These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 19841030)
1. Comment on: Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin. Adriaenssens N; Goossens H; Coenen S; J Antimicrob Chemother; 2009 Dec; 64(6):1347. PubMed ID: 19841030 [No Abstract] [Full Text] [Related]
2. Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin. Nathwani D J Antimicrob Chemother; 2009 Sep; 64(3):447-53. PubMed ID: 19584105 [TBL] [Abstract][Full Text] [Related]
3. Experience with daptomycin in an infectious diseases service over 1 year: utility in an outpatient parenteral antibiotic programme. Seaton RA; Macconnachie AA Int J Antimicrob Agents; 2008 May; 31(5):492-7. PubMed ID: 18313274 [No Abstract] [Full Text] [Related]
4. Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study. Shrestha NK; Mason P; Gordon SM; Neuner E; Nutter B; O'Rourke C; Rehm SJ J Antimicrob Chemother; 2014 May; 69(5):1407-15. PubMed ID: 24398341 [TBL] [Abstract][Full Text] [Related]
12. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. Kern WV Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659 [TBL] [Abstract][Full Text] [Related]
13. [Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias]. Hernández Martí V; Romá Sánchez E; Salavert Lletí M; Bosó Ribelles V; Poveda Andrés JL Rev Esp Quimioter; 2007 Sep; 20(3):261-76. PubMed ID: 18080024 [TBL] [Abstract][Full Text] [Related]
14. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. Steenbergen JN; Alder J; Thorne GM; Tally FP J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644 [TBL] [Abstract][Full Text] [Related]
15. European Surveillance of Antimicrobial Consumption (ESAC): outpatient parenteral antibiotic treatment in Europe. Coenen S; Muller A; Adriaenssens N; Vankerckhoven V; Hendrickx E; Goossens H; J Antimicrob Chemother; 2009 Jul; 64(1):200-5. PubMed ID: 19383728 [TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy. Schrank GM; Wright SB; Branch-Elliman W; LaSalvia MT Infect Control Hosp Epidemiol; 2018 Aug; 39(8):947-954. PubMed ID: 29893658 [TBL] [Abstract][Full Text] [Related]
17. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. French GL J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922 [TBL] [Abstract][Full Text] [Related]
18. Early experience with high-dosage daptomycin for prosthetic infections. De Rosa FG; Mollaretti O; Cometto C; Pagani N; Montrucchio C; Di Perri G Clin Infect Dis; 2009 Dec; 49(11):1772-3. PubMed ID: 19891570 [No Abstract] [Full Text] [Related]
19. Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers. Sader HS; Watters AA; Fritsche TR; Jones RN J Chemother; 2008 Feb; 20(1):28-32. PubMed ID: 18343740 [TBL] [Abstract][Full Text] [Related]